biology

Prefibrotic primary myelofibrosis

Prefibrotic primary myelofibrosis is a biology topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Prefibrotic primary myelofibrosis rather than just read about it. In short: Prefibrotic primary myelofibrosis (Pre-PMF) is a rare blood cancer, classified by the World Health Organization as a distinct type of myeloproliferative neoplasm in 2016. The disease is progressive to overt primary myelofibrosis, though the rate of progression is variable and not all patients progress.

Key takeaways

Prefibrotic primary myelofibrosis belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Prefibrotic primary myelofibrosis to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Prefibrotic primary myelofibrosis from memory before moving on to harder problems.

Reference excerpt

Prefibrotic primary myelofibrosis (Pre-PMF) is a rare blood cancer, classified by the World Health Organization as a distinct type of myeloproliferative neoplasm in 2016. The disease is progressive to overt primary myelofibrosis, though the rate of progression is variable and not all patients progress. Symptoms and presentation can mimic essential thrombocythemia, with the main differentiator for pre-PMF being the presence of fibrosis in the bone marrow.

Diagnosis A bone marrow examination is required for diagnosis.

Major Criteria The bone marrow histology should demonstrate the following:

A proliferation and atypia of the bone marrow cells that produce platelets (megakaryocytes) Reticulin fibrosis which doesn't exceed grade 1. Grade 2 or 3 is a diagnostic criteria for primary myelofibrosis. Age-adjusted cellularity Proliferation of granulocytes, a type of white blood cell Decreased production of red blood cells (erythropoiesis) Presence of JAK2, CALR, MPL or other clonal marker.

Minor Criteria According to the WHO, at least one of these minor criteria should be present:

Anemia which is not attributable to another condition High white blood cell count (leukocytosis) An enlarged spleen (splenomegaly) LDH levels above the upper limit of the reference range.

Comparison with primary myleofibrosis Reticulin or collagen fibrosis grade 2 or 3 is a diagnostic criteria for primary myelofibrosis.

Comparison with Essential Thrombocythemia Both pre-PMF and Essential thrombocythemia can share diagnostic similarities, such as a proliferation of megakaryocytes and a presence of a mutation. The presence of Reticulin fibrosis in pre-PMF provides the clearest distinction between the two.

Treatment Patients considered low risk for thrombosis or major bleeding should be observed only. Low-dose aspirin is recommended for patients without a history of thrombosis. For intermediate risk patients, symptom driven therapy for anaemia or constitutional symptoms. For high risk patients with a history of thrombosis, oral anticoagulants and cytoreductive drugs such as hydroxycarbamide are recommended, and the patient should be treated as in primary myelofibrosis.

Prognosis Prognosis of pre-PMF currently suffers from a lack of multi-center data, with several biases resulting from the disease being newly distinct in WHO's 2016 reclassification. The 10 year cumulative incidence of progression to overt PMF is between 9.7 and 31.5%. The 10 year incidence of transformation into acute myeloid leukemia ranges from 5.8% to 12%. A prognostic scoring model designed specifically for pre-PMF does not yet exist, but the International Prognostic Scoring System can be used to predict survival in pre-PMF patients. A multi-center study on reclassified PMF patients showed median survival of pre-PMF patients at 17.6 years compared with 7.2 years for overt PMF patients. However, another study showed 98% of pre-PMF patients were alive after 10 years from diagnosis and while overt PMF patients showed a median survival of 16.6 years, pre-PMF median survival was not able to be calculated as more than 50% of patients were still alive at the time of publication.

History First described in 1976, pre-PMF was not introduced into the WHO's classification of tumors until 2001, and not formally classified as a distinct entity until the 2016 revision.

References

Worked examples

Example 1 — a first encounter with Prefibrotic primary myelofibrosis

Start with the simplest possible case. Write down what Prefibrotic primary myelofibrosis claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Prefibrotic primary myelofibrosis before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Prefibrotic primary myelofibrosis ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Prefibrotic primary myelofibrosis

In research: Prefibrotic primary myelofibrosis appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Prefibrotic primary myelofibrosis in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Prefibrotic primary myelofibrosis is common in secondary-school and first-year university syllabi. It links to neighbouring topics Idiopathic diseases, Myeloid neoplasia, Rare cancers, so understanding it makes those chapters shorter.
In everyday life: Look for Prefibrotic primary myelofibrosis outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Prefibrotic primary myelofibrosis” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Prefibrotic primary myelofibrosis in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Prefibrotic primary myelofibrosis means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Prefibrotic primary myelofibrosis out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Prefibrotic primary myelofibrosis in simple terms?

Why does Prefibrotic primary myelofibrosis matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Prefibrotic primary myelofibrosis?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Prefibrotic primary myelofibrosis.